Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (161-170 of 192) with videos related to

Pageof 20
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trialRyota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
JAMA Network Open|July 11, 2023
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung CancerHayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2021
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)Yoshihiko Sakata, Shinya Sakata, Yuko Oya, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2022
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort studyMihoko Imaji, Daichi Fujimoto, Yuki Sato, et al.
Chest|June 6, 2022
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World SettingYuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT studyAsuka Okada, Yoshihiko Sakata, Yuko Oya, et al.
JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
Pageof 20

Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trialRyota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
JAMA Network Open|July 11, 2023
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung CancerHayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2021
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)Yoshihiko Sakata, Shinya Sakata, Yuko Oya, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2022
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort studyMihoko Imaji, Daichi Fujimoto, Yuki Sato, et al.
Chest|June 6, 2022
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World SettingYuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT studyAsuka Okada, Yoshihiko Sakata, Yuko Oya, et al.
JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
Pageof 20